Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety
Combining TACE with tislelizumab-TKIs significantly improves survival over systemic therapy alone in unresectable HCC, with maximal benefit observed in patients aged ≥60 years, without extrahepatic spread, with AFP <400 ng/mL, or normal GGT, despite increased manageable toxicity.
Authors
- Zhenxue Cao
- Song Wang (ORCID: https://orcid.org/0000-0003-1135-7518)
- Shuai Chang (ORCID: https://orcid.org/0000-0001-7405-5555)
- Jian Li (ORCID: https://orcid.org/0000-0003-4461-6686)
- Qun Li (ORCID: https://orcid.org/0000-0002-9128-5405)
- Shuo Zhang (ORCID: https://orcid.org/0000-0001-8171-2779)
- Chunpeng Yu
- Fengliang Wang (ORCID: https://orcid.org/0009-0007-4187-5777)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
- Qingdao Eighth People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1664519
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00